Stockscreener 앱 받기
6.47
4.52%
0.28
시간 외 거래:
6.41
-0.06
-0.93%
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha
Can Candel Therapeutics Inc. stock sustain revenue growthEarnings Risk Report & Technical Confirmation Alerts - newser.com
Will Candel Therapeutics Inc. stock deliver strong dividend growth2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
What MACD signals say about Candel Therapeutics Inc.Market Risk Report & Real-Time Volume Analysis - newser.com
Analyzing drawdowns of Candel Therapeutics Inc. with statistical tools2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
How to interpret RSI for Candel Therapeutics Inc. stockWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Is Candel Therapeutics Inc a good long term investmentProtective Put Strategies & Outstanding Wealth Building - earlytimes.in
Visual trend scoring systems applied to Candel Therapeutics Inc.July 2025 Price Swings & High Win Rate Trade Tips - newser.com
Price momentum metrics for Candel Therapeutics Inc. explainedWeekly Trading Summary & Community Verified Trade Signals - newser.com
Candel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How resilient is Candel Therapeutics Inc. stock in market downturns2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Candel Therapeutics Inc. stock bottoming outQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Why Candel Therapeutics Inc. stock remains undervalued2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Candel Therapeutics to present insights from enLIGHTEN Discovery Platform at SITC 2025 meeting - Proactive financial news
Candel Therapeutics to Present at the SITC 2025 Annual Meeting - The Manila Times
Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting - Quiver Quantitative
Positive Phase 3 CAN-2409 data — Candel Therapeutics presents prostate cancer & NSCLC at SITC Nov 2025 - Stock Titan
Is Candel Therapeutics Inc. stock a smart buy before Fed meetingMarket Growth Summary & Stock Portfolio Risk Control - newser.com
Using Ichimoku Cloud for Candel Therapeutics Inc. technicals2025 Buyback Activity & Precise Buy Zone Tips - newser.com
Candel Therapeutics’ CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial - Proactive financial news
Tanager Wealth Management LLP Purchases New Shares in Candel Therapeutics, Inc. $CADL - MarketBeat
H.C. Wainwright reiterates Buy rating on Candel Therapeutics stock at $23 price target - Investing.com Australia
Candel Therapeutics Inc. stock retracement – recovery analysisLayoff News & Daily Growth Stock Investment Tips - newser.com
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - 富途牛牛
HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation - Nasdaq
CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating | CADL Stock News - GuruFocus
CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating - GuruFocus
HC Wainwright Reiterates "Buy" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewswire
Candel Therapeutics presents phase 3 clinical trial of CAN-2409 - MarketScreener
Candel trial shows promise for gene therapy in prostate cancer - Proactive financial news
Candel Therapeutics Reports Positive Phase 3 Trial Results for CAN-2409 in Intermediate-to-High-Risk Localized Prostate Cancer at ASTRO 2025 - Quiver Quantitative
30% Better Survival: Candel's Breakthrough Prostate Cancer Drug Shows Success Across All Radiation Types - Stock Titan
1.11%
자본화:
|
볼륨(24시간):